- SEK152.95m
- SEK151.82m
- SEK163.02m
- 90
- 38
- 73
- 79
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 15.25 | ||
PEG Ratio (f) | 0.33 | ||
EPS Growth (f) | 87.37% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 3.14 | ||
Price to Tang. Book | 5.23 | ||
Price to Free Cashflow | 9.21 | ||
Price to Sales | 0.94 | ||
EV to EBITDA | 13.31 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 9.18% | ||
Return on Equity | 5.42% | ||
Operating Margin | 2.86% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | SEKm | 133.67 | 117.42 | 117.13 | 125.05 | 163.01 | 179 | 195 | 6.41% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | -67.7 | n/a | n/a | +17.93 | +152.17 | +28.57 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Arcoma AB is a Sweden-based medical technology company. It develops, produces and markets digital radiographic systems. Its products offer digital imaging technology combined with advanced mobile positioning system. The Company's product portfolio comprises: complete radiographic systems available as ceiling suspensions and floor mounted systems, as well as detectors; radiographic system components, such as overhead tube crane, cube, tilting wall stand and radiographic tables; and mobile imaging tables in two series, namely Precision and Elite. Its products are designed for hospitals, clinics, imaging centers and private practices, and available through three market channels: its own brand IMIX, private label distributors and original equipment manufacturers (OEM).
Directors
- Lars Kvarnhem CHM (49)
- Sanna Rydberg CEO (52)
- Johan Henningsson VRD (50)
- Mattias Rundgren CTR (43)
- Frida Robbe DMK (36)
- Nicklas Johansson OTH (54)
- Katja Kristensson OTH (38)
- Jesper Lindroos OTH (37)
- Linda Ungsten OTH (47)
- Anders Dahlberg DRC (45)
- Jesper Soderqvist DRC (55)
- Mats Thoren DRC (50)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 11th, 1990
- Public Since
- November 14th, 2014
- No. of Employees
- 31
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 13,185,560
- Address
- Annavagen 1, VAXJO, 352 46
- Web
- https://www.arcoma.se/
- Phone
- +46 470706900
- Auditors
- Deloitte AB
Upcoming Events for ARCOMA
Arcoma AB Annual Shareholders Meeting
Arcoma AB Annual Shareholders Meeting
Q2 2024 Arcoma AB Earnings Release
Similar to ARCOMA
Acarix AB
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
Aegirbio AB
OMX Nordic Exchange Stockholm
Arjo AB (publ)
OMX Nordic Exchange Stockholm
FAQ
As of Today at 19:02 UTC, shares in Arcoma AB are trading at SEK11.60. This share price information is delayed by 15 minutes.
Shares in Arcoma AB last closed at SEK11.60 and the price had moved by +29.61% over the past 365 days. In terms of relative price strength the Arcoma AB share price has outperformed the FTSE Global All Cap Index by +21.68% over the past year.
There is no consensus recommendation for this security.
Arcoma AB does not currently pay a dividend.
Arcoma AB does not currently pay a dividend.
Arcoma AB does not currently pay a dividend.
To buy shares in Arcoma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK11.60, shares in Arcoma AB had a market capitalisation of SEK152.95m.
Here are the trading details for Arcoma AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ARCOMA
Based on an overall assessment of its quality, value and momentum Arcoma AB is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcoma AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +46.24%.
As of the last closing price of SEK11.60, shares in Arcoma AB were trading +27.76% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Arcoma AB PE ratio based on its reported earnings over the past 12 months is 15.25. The shares last closed at SEK11.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Arcoma AB's management team is headed by:
- Lars Kvarnhem - CHM
- Sanna Rydberg - CEO
- Johan Henningsson - VRD
- Mattias Rundgren - CTR
- Frida Robbe - DMK
- Nicklas Johansson - OTH
- Katja Kristensson - OTH
- Jesper Lindroos - OTH
- Linda Ungsten - OTH
- Anders Dahlberg - DRC
- Jesper Soderqvist - DRC
- Mats Thoren - DRC